[
  {
    "ts": null,
    "headline": "Why The Narrative Around AbbVie Is Shifting After New Immunology And Valuation Updates",
    "summary": "AbbVie’s latest narrative update leaves its fair value estimate steady at roughly $243.55 per share, even as small tweaks to the model reflect a slightly higher discount rate, a touch softer revenue growth outlook, and a modestly lower future valuation multiple applied to earnings. These shifts echo a market balancing act between enthusiasm over durable immunology growth, extended Rinvoq exclusivity, and sector rerating potential, and caution around pipeline execution risks, legacy asset...",
    "url": "https://finnhub.io/api/news?id=7a22758e4e07ed50769c604d0603a42e9e8c2f0343f8879b554266502bb3e37e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765235552,
      "headline": "Why The Narrative Around AbbVie Is Shifting After New Immunology And Valuation Updates",
      "id": 137737758,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie’s latest narrative update leaves its fair value estimate steady at roughly $243.55 per share, even as small tweaks to the model reflect a slightly higher discount rate, a touch softer revenue growth outlook, and a modestly lower future valuation multiple applied to earnings. These shifts echo a market balancing act between enthusiasm over durable immunology growth, extended Rinvoq exclusivity, and sector rerating potential, and caution around pipeline execution risks, legacy asset...",
      "url": "https://finnhub.io/api/news?id=7a22758e4e07ed50769c604d0603a42e9e8c2f0343f8879b554266502bb3e37e"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Falls More Steeply Than Broader Market: What Investors Need to Know",
    "summary": "AbbVie (ABBV) concluded the recent trading session at $223.12, signifying a -1.31% move from its prior day's close.",
    "url": "https://finnhub.io/api/news?id=bbc714b28b502e4a621546800fcd0cab3d52b6065f1479d7bee49fbf964f9335",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765233902,
      "headline": "AbbVie (ABBV) Falls More Steeply Than Broader Market: What Investors Need to Know",
      "id": 137737759,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) concluded the recent trading session at $223.12, signifying a -1.31% move from its prior day's close.",
      "url": "https://finnhub.io/api/news?id=bbc714b28b502e4a621546800fcd0cab3d52b6065f1479d7bee49fbf964f9335"
    }
  },
  {
    "ts": null,
    "headline": "How Investors May Respond To AbbVie (ABBV) Expanding Its Pipeline With New Migraine And Oncology Data",
    "summary": "In recent weeks, AbbVie has reported positive clinical and regulatory updates across several franchises, including strong Phase 3 migraine data for atogepant, encouraging early-stage blood cancer results for PVEK, and expanded Canadian reimbursement for SKYRIZI in ulcerative colitis. Together with an amended development arrangement for the early-stage antibody ABBV-230, these developments highlight how AbbVie is broadening its pipeline beyond its established immunology and neuroscience...",
    "url": "https://finnhub.io/api/news?id=7986308e4e7cc4902e16a8440e5b029e403d6d749ae955060da5d1a8e51924fb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765220832,
      "headline": "How Investors May Respond To AbbVie (ABBV) Expanding Its Pipeline With New Migraine And Oncology Data",
      "id": 137737760,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "In recent weeks, AbbVie has reported positive clinical and regulatory updates across several franchises, including strong Phase 3 migraine data for atogepant, encouraging early-stage blood cancer results for PVEK, and expanded Canadian reimbursement for SKYRIZI in ulcerative colitis. Together with an amended development arrangement for the early-stage antibody ABBV-230, these developments highlight how AbbVie is broadening its pipeline beyond its established immunology and neuroscience...",
      "url": "https://finnhub.io/api/news?id=7986308e4e7cc4902e16a8440e5b029e403d6d749ae955060da5d1a8e51924fb"
    }
  },
  {
    "ts": null,
    "headline": "Top-Ranked ETFs to Power Your Portfolio Higher",
    "summary": "With market tailwinds building and optimism returning, these top-ranked ETFs can help investors capture momentum safely.",
    "url": "https://finnhub.io/api/news?id=09c653a2074e50b91ca5b1a50357c2a1f772e3bb6bf997344c8c5d344dbcbec6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765209180,
      "headline": "Top-Ranked ETFs to Power Your Portfolio Higher",
      "id": 137737705,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "With market tailwinds building and optimism returning, these top-ranked ETFs can help investors capture momentum safely.",
      "url": "https://finnhub.io/api/news?id=09c653a2074e50b91ca5b1a50357c2a1f772e3bb6bf997344c8c5d344dbcbec6"
    }
  },
  {
    "ts": null,
    "headline": "2026 Market Outlook: S&P 500 To 7600, Healthcare, Renewable Energy, Industrials Will Lead",
    "summary": "Discover why the S&P 500 could hit $7,600 by 2026, driven by AI, sector rotation, and strong consumer trends. Click for my look into the market's future.",
    "url": "https://finnhub.io/api/news?id=9cc1b002a6efaf1fddb5bd4fe481b718786c0396d00abeff24f5abc6760c3a0e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765205708,
      "headline": "2026 Market Outlook: S&P 500 To 7600, Healthcare, Renewable Energy, Industrials Will Lead",
      "id": 137734426,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1334805030/image_1334805030.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Discover why the S&P 500 could hit $7,600 by 2026, driven by AI, sector rotation, and strong consumer trends. Click for my look into the market's future.",
      "url": "https://finnhub.io/api/news?id=9cc1b002a6efaf1fddb5bd4fe481b718786c0396d00abeff24f5abc6760c3a0e"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention?",
    "summary": "Regeneron beats earnings, expands partnerships, and gains EU approval for Dupixent.",
    "url": "https://finnhub.io/api/news?id=bc1dea061d8db4e845af0efe1ebf320e8d00b4b0abdcf4f3046341681c9391d7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765205192,
      "headline": "Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention?",
      "id": 137734429,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2118024278/image_2118024278.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Regeneron beats earnings, expands partnerships, and gains EU approval for Dupixent.",
      "url": "https://finnhub.io/api/news?id=bc1dea061d8db4e845af0efe1ebf320e8d00b4b0abdcf4f3046341681c9391d7"
    }
  },
  {
    "ts": null,
    "headline": "OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development",
    "summary": "OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development Strategic Amendment Enhances OSE Immunotherapeutics’ Role in ABBV-230 Development While Preserving AbbVie’s Long-Term Commitment NANTES, France, December 8th, 2025 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced an amendment to its partnership agreement with AbbVie regarding ABBV-230, a monoclonal antibody designed to resolve chronic and severe inflammati",
    "url": "https://finnhub.io/api/news?id=cf128cef0c8417faf7a0cc2e62dd6c7c8bf7e8a7d895a0dcb76c3d1723d92a7f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765175400,
      "headline": "OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development",
      "id": 137732260,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development Strategic Amendment Enhances OSE Immunotherapeutics’ Role in ABBV-230 Development While Preserving AbbVie’s Long-Term Commitment NANTES, France, December 8th, 2025 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced an amendment to its partnership agreement with AbbVie regarding ABBV-230, a monoclonal antibody designed to resolve chronic and severe inflammati",
      "url": "https://finnhub.io/api/news?id=cf128cef0c8417faf7a0cc2e62dd6c7c8bf7e8a7d895a0dcb76c3d1723d92a7f"
    }
  }
]